| Name | Enmetazobactam |
| Description | Enmetazobactam (AAI101) is an extended-spectrum β-lactamase inhibitor used to treat multi-drug resistant gram-negative bacterial infections. |
| In vitro | Enmetazobactam, a novel extended-spectrum β-lactamase inhibitor.Of the 223 cefepime non-susceptible isolates, 95% were ceftazidime non-susceptible, 49% ertapenem non-susceptible, 57% piperacillin/tazobactam non-susceptible, 90% were multidrug-resistant (resistant to 3 drug classes), 22% produced carbapenemases, and 67% produced ESBLs.Addition of Enmetazobactam restored the activity of cefepime such that the MIC50 was reduced from >64 mg/L for cefepime to 0.13 mg/L for cefepime/Enmetazobactam, supporting its continued development treatment for infections caused by these organisms.Enmetazobactam shows potent activity against specific resistance phenotypes with MIC50 and MIC90 of 0.125 mg/L and 64 mg/L[1].Cefepime-Enmetazobactam MICs decreases with increasing concentrations of Enmetazobactam (over the range from 1 to 16 mg/L) for most strains.which is demonstrating a concentration dependence of Enmetazobactam on restoration of the antibacterial activity of the cephalosporin[1]. |
| In vivo | Against a panel of 20 mostly carbapenemase-producing cefepime-nonsusceptible strains of the family Enterobacteriaceae, we evaluated the MICs of cefepime in the presence of various fixed Enmetazobactam concentrations (1, 2, 4, 8, and 16 mg/liter) and the in vivo efficacy of simulated human doses of cefepime and cefepime-Enmetazobactam in a neutropenic murine thigh infection model.At 2 h after inoculation, mice were dosed with regimens that provided a profile mimicking the free drug concentration-time profile observed in humans given cefepime at 2 g every 8 h (q8h;as a 30-min infusion) or cefepime-Enmetazobactam at 2 g/0.5 g q8h (as a 30-min infusion).Efficacy was determined by calculation of the change in thigh bacterial density (log10 number of CFU) after 24 h relative to the starting inoculum (0 h). After 24 h, bacterial growth of 2.7 0.1 log10 CFU (mean standard error) was observed in control animals.Efficacy for cefepime monotherapy was observed against only 3 isolates, whereas increases in bacterial density similar to that in the control animals were noted for the remaining 17 strains (all with cefepime MICs of 64 mg/liter).The humanized cefepime-Enmetazobactam dosing regimen resulted in bacterial reductions of 0.5 log10 CFU for 12 of the 20 strains[2]. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (12.73 mM), Sonication is recommended.
DMSO : 150 mg/mL (477.22 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | Enmetazobactam | Bacterial | AAI-101 | AAI 101 |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | Drug Repurposing Compound Library | Beta-Lactam Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Bacterial Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Infection Compound Library |
United States
